Publications by authors named "C A Presant"
Background: In a previously reported Phase I trial, we observed therapy-associated declines in circulating myeloid-derived suppressor cells (MDSCs) with the administration of white button mushroom (WBM) tablets in prostate cancer (PCa) patients. These observations led us to hypothesise that WBM could mitigate PCa progression by suppressing MDSCs.
Methods: We performed bidirectional translational research to examine the immunomodulatory effects of WBM consumption in both syngeneic murine PCa models and patients with PCa participating in an ongoing randomised Phase II trial (NCT04519879).
Article Synopsis
- Tobacco use significantly increases cancer-related mortality, yet the prevalence and factors influencing smoking among cancer clinical trial participants are not well understood.
- A study involving 4,326 patients from SWOG cancer trials (2016-2022) found that 48.1% reported a history of smoking, with certain demographics more likely to have smoked, including older males and those with lower socioeconomic status.
- The findings emphasize the need for routine assessment of smoking status in clinical trials to address health disparities and mitigate the adverse effects of smoking in cancer patients.
Overcoming Delays in the Progress against Cancer: Identifying Tobacco Use among Cancer Patients Enrolled in Clinical Trials.
Cancer Epidemiol Biomarkers Prev
May 2024
Though smoking causes adverse cancer treatment outcomes and smoking cessation can improve survival, prior literature demonstrates deficits in collecting tobacco use information in clinical trials. Results by Streck and colleagues represent a thorough structured assessment of tobacco use and alternative tobacco product use in patients enrolled in cooperative group trials. Among patients with predominantly non-tobacco related cancers, observations demonstrate that approximately 27% of patients reported using one or more forms of tobacco use after diagnosis.
View Article and Find Full Text PDFBackground: The Cancer Center Cessation Initiative (C3I) is a National Cancer Institute (NCI) Cancer Moonshot Program that supports NCI-designated cancer centers developing tobacco treatment programs for oncology patients who smoke. C3I-funded centers implement evidence-based programs that offer various smoking cessation treatment components (e.g.
View Article and Find Full Text PDFArticle Synopsis
- * New tobacco control services were introduced, including motivational counseling, clinician champions, and a patient-centered program called Personalized Pathways to Success (PPS) aimed at improving engagement and outcomes.
- * Results showed increased lung cancer screenings, higher tobacco use assessments, and a notable 27.2% cessation rate, with the PPS program achieving 47% engagement and 38% self-reported abstinence at 3 months, particularly benefiting minority patients.